



RONG YU PHARMACEUTICALS LIMITED
ACN 617 647 293

SUPPLEMENTARY PROSPECTUS

THIS IS A SUPPLEMENTARY PROSPECTUS TO THE REPLACEMENT PROSPECTUS LODGED WITH ASIC ON 31 OCTOBER 2017 (PROSPECTUS).

THIS SUPPLEMENTARY PROSPECTUS MUST BE READ TOGETHER WITH THE PROSPECTUS.

THIS IS AN IMPORTANT DOCUMENT AND SHOULD BE READ IN ITS ENTIRETY.

IF YOU ARE IN DOUBT ABOUT WHAT TO DO, YOU SHOULD CONSULT YOUR PROFESSIONAL ADVISOR WITHOUT DELAY.

1. IMPORTANT INFORMATION

This is a supplementary prospectus dated 20 December 2017 (**Supplementary Prospectus**). This Supplementary Prospectus should be read in conjunction with the replacement prospectus dated 31 October 2017 (**Prospectus**) issued by Rong Yu Pharmaceuticals Limited ACN 617 647 293 (**Company**). A copy of this Supplementary Prospectus was lodged with ASIC on 20 December 2017.

Terms defined in the Prospectus have the same meaning in this Supplementary Prospectus, unless otherwise indicated.

This Supplementary Prospectus and the Prospectus may be viewed on the Company's website at <http://en.rongyupharma.com/>. You may obtain a paper copy of the Prospectus and this Supplementary Prospectus by contacting the Company.

This document is important and should be read in its entirety and in conjunction with the Prospectus. If there is a conflict between the Prospectus and this Supplementary Prospectus, this Supplementary Prospectus will prevail. If you do not understand the contents of this Supplementary Prospectus, you should consult your professional advisor without delay. Neither ASIC nor ASX takes any responsibility for the contents of this Supplementary Prospectus.

2. EXTENSION OF OFFER PERIOD

The purpose of this Supplementary Prospectus is to extend the Offer Closing Date to 5pm (AEST) Friday, 29 December 2017. Accordingly, the key dates as set out on page 6 of the Prospectus and references to each corresponding date in the Prospectus have been updated as follows:

Event	Date (AEST)
Original Prospectus lodged with ASIC	16 October 2017
Prospectus lodged with ASIC	31 October 2017
Supplementary Prospectus lodged with ASIC	20 December 2017
Prospectus Offer closes	29 December 2017
Expected Allotment Date of Offer Shares	5 January 2018
Expected dispatch of Holding Statements	9 January 2018
Admission of Company to ASX	12 January 2018

**Please note that the dates set out in the above timetable may be varied in accordance with the Corporations Act, and, where required, in consultation with ASX. These dates are indicative only and are subject to change. The Company reserves the right to vary the dates without prior notice.*

3. APPLICATIONS

The Directors believe that the changes set out in this Supplementary Prospectus are not materially adverse from the point of view of an investor.

Accordingly no action needs to be taken if you have already subscribed for Offer Shares under the Prospectus. Applicants who have already applied for Offer Shares under the Prospectus are not required to re-submit an Application Form unless they wish to apply for additional Offer Shares.

The Application Form enclosed with the Prospectus remains valid and applications for Offer Shares under the Supplementary Prospectus must be made using the Application Form.

This Supplementary Prospectus is intended to be read in conjunction with the Replacement Prospectus dated 31 October 2017, relating to the shares of Rong Yu Pharmaceuticals Limited ACN 617 647 293.

Applicants who would like to apply for Offer Shares should contact the Share Registry, Security Transfer Australia on 1300 992 916 (within Australia) or +618 9315 2233 (outside Australia), from 8.30am to 5.00pm (Monday to Friday).


4. DIRECTORS' AUTHORISATION

This Supplementary Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors.

In accordance with section 720 of the *Corporations Act 2001* (Cth), each Director has consented to the lodgement of this Supplementary Prospectus with ASIC.

Date: 20 December 2017

Signed for and behalf of Rong Yu Pharmaceuticals Limited



Phillip Grundy

Non-Executive Director